1. Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2017.6
Figure 4 Engineering nuclease-deactivated Cas9 (dCas9) for gene activation and repression
Figure 4 | Engineering nuclease-deactivated Cas9 (dCas9) for gene activation and repression. Several strategies can be used to generate gene activators: a | fusion of dCas9 with three activator domains, namely the herpes simplex activation domain (VP64), transcription factor p65 and the Epstein–Barr virus replication and transcription activator (Rta) (together known as VPR); b | an array of small peptide epitopes fused to dCas9 to recruit multiple copies of single chain variable fragment fused to VP64 (Sun Tag); or c | a modified guide RNA (gRNA) encoding extra loop structures that bind to the MS2 coat protein (MCP) that is in turn fused to p65 and heat shock factor 1 (HSF1). d | Similar strategies are employed for the generation of gene repressors and include fusion of dCas9 with the repressor domain Krüppel-associated box (KRAB). Modified with permission from NPG © Chavez, A. et al. Nat. Methods 13, 563–567 (2016).
Modified with permission from NPG © Chavez, A. et al. Nat. Methods 13, 563–567 (2016).
Gibson, G. J. & Yang, M. (2017) What rheumatologists need to know about CRISPR/Cas9
Nat. Rev. Rheumatol. doi: /nrrheum